Idelalisib - Gilead Sciences

Drug Profile

Idelalisib - Gilead Sciences

Alternative Names: CAL-101; GS-1101; Zydelig

Latest Information Update: 06 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Calistoga Pharmaceuticals
  • Developer Augusta University; Calistoga Pharmaceuticals; Celgene Corporation; Gilead Sciences; Merck Sharp & Dohme; National Cancer Institute (USA)
  • Class Antineoplastics; Purines; Quinazolinones; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Follicular lymphoma
  • Phase III Non-Hodgkin's lymphoma
  • Phase II Hodgkin's disease; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Non-small cell lung cancer
  • Phase I Diffuse large B cell lymphoma
  • No development reported Myelofibrosis; Pancreatic cancer
  • Discontinued Allergic rhinitis; Solid tumours

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Monotherapy, Second-line therapy or greater) in Japan (PO, Tablet)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Follicular lymphoma(Combination therapy, Recurrent) in USA (PO, Tablet)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Follicular lymphoma(Monotherapy, Second-line therapy or greater) in Japan (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top